SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Pyxis Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

(CUSIP Number)

09/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BIOTECHNOLOGY VALUE FUND L P
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 6,250,280.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 6,250,280.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 6,250,280.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 5.2 %
12		Type of Reporting Person (See Instructions) PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons BVF I GP LLC
2		Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 6,250,280.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 6,250,280.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 6,250,280.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐

11	Percent of class represented by amount in row (9)	5.2 %
12	Type of Reporting Person (See Instructions)	OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	BIOTECHNOLOGY VALUE FUND II LP
2	Check the appropriate box if a member of a Group (see instructions)	☑ (a) ☐ (b)
3	Sec Use Only	
4	Citizenship or Place of Organization	DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power	0.00
	6 Shared Voting Power	4,609,217.00
	7 Sole Dispositive Power	0.00
	8 Shared Dispositive Power	4,609,217.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person	4,609,217.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	☐
11	Percent of class represented by amount in row (9)	3.9 %
12	Type of Reporting Person (See Instructions)	PN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	BVF II GP LLC
2	Check the appropriate box if a member of a Group (see instructions)	

☑ (a)
☐ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

4,609,217.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

4,609,217.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

4,609,217.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

11 Percent of class represented by amount in row (9)

3.9 %

12 Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons

Biotechnology Value Trading Fund OS LP

2 Check the appropriate box if a member of a Group (see instructions)

☑ (a)
☐ (b)

3 Sec Use Only

4 Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

844,116.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

844,116.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

844,116.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

0.7 %

Type of Reporting Person (See Instructions)

12

PN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

BVF Partners OS Ltd.

Check the appropriate box if a member of a Group (see instructions)

2

☑ (a)
☐ (b)

3 Sec Use Only

Citizenship or Place of Organization

4

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

844,116.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

844,116.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

844,116.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

0.7 %

Type of Reporting Person (See Instructions)

12

CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BVF GP HOLDINGS LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 10,859,497.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 10,859,497.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 10,859,497.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.1 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons BVF PARTNERS L P/IL	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each	5	Sole Voting Power 0.00
	6	Shared Voting Power

Reporting Person With:		11,945,583.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 11,945,583.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 11,945,583.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.99 %
12		Type of Reporting Person (See Instructions) IA, PN

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons BVF INC/IL
2		Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 11,945,583.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 11,945,583.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 11,945,583.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 9.99 %
12		Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons LAMPERT MARK N	
2	Check the appropriate box if a member of a Group (see instructions) ☑ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 11,945,583.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 11,945,583.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 11,945,583.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.99 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Pyxis Oncology, Inc.

(b) Address of issuer's principal executive offices:

321 HARRISON AVENUE, BOSTON, MA 02118

Item 2.

(a) Name of person filing:

Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

(b) Address or principal business office or, if none, residence:

Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104

(c) Citizenship:

Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States

(d) Title of class of securities:

Common Stock, par value $0.001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on September 30, 2026, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held an aggregate of 7,840,062 Warrants (the "Warrants") exercisable for an aggregate of 7,840,062 shares of the Issuer's Common Stock, par value $0.001 per share (the "Shares"). The Warrants are exercisable at an exercise price per Share equal to $3.289 per Share and may be exercised at any time, and will expire on July 2, 2029. A holder of the Warrants shall not have the right to exercise any portion of the Warrants if the holder, together with its affiliates, beneficially owns or would beneficially own in excess of 9.99% of the Shares that would be issued and outstanding following such exercise (the "Maximum Percentage"). As of the close of business on September 30, 2026, the Maximum Percentage prohibited the exercise of all of the Warrants held by the Reporting Persons and the Partners Managed Account. As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 1,185,922 Shares. The Pre-Funded Warrants are exercisable at any time at an exercise price of $0.001 per Share and will not expire until exercised in full. Under the pre-funded warrants, the Issuer may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of Shares greater than 9.99% of the number of Shares outstanding immediately before giving effect to the exercise of any Pre-Funded Warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of such Shares, and without taking into account any other Pre-Funded Warrants (the

"Pre-Funded Warrants Blocker"). As of the close of business on September 30, 2026, the Pre-Funded Warrants Blocker limits the exercise of the Pre-Funded Warrants by the Reporting Persons and the Partners Managed Account to 119,443 out of 1,185,922 Shares underlying the Pre-Funded Warrants held by them. As of the close of business on September 30, 2026, the Reporting Persons and the Partners Managed Account held an aggregate of 6,723,600 common warrants (the "Common Warrants") exercisable for an aggregate of 6,723,600 Shares. The Common Warrants are exercisable at any time at an exercise price of $3.50 per Share. The Common Warrants will expire at 5:00 p.m. (New York City time) on the earlier of (A) the fifth anniversary of November 13, 2026 (the "Charter Amendment Effective Date") and (B) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the Issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and later recurrent or metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC), which is expected in the first half of 2027. Under the Common Warrants, the Issuer may not effect the exercise of any Common Warrant, and a holder will not be entitled to exercise any portion of any Common Warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of Shares greater than 9.99% of the number of Shares outstanding immediately before giving effect to the exercise of any Common Warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of such Shares, and without taking into account any other Common Warrants (the "Common Warrants Blocker"). As of the close of business on September 30, 2026, the Common Warrants Blocker prohibited the exercise of all of the Common Warrants held by the Reporting Persons and the Partners Managed Account. As of the close of business on September 30, 2026, (i) BVF beneficially owned 6,250,280 Shares, including 119,443 Shares underlying certain Pre-Funded Warrants held by it and excluding (a) 480,287 Shares underlying certain Pre-Funded Warrants held by it, (b) 3,400,176 Shares underlying certain Common Warrants held by it and (c) 4,115,047 Shares underlying the Warrants held by it, (ii) BVF2 beneficially owned 4,609,217 Shares, excluding (a) 453,820 Shares underlying the Pre-Funded Warrants held by it, (b) 2,572,947 Shares underlying the Common Warrants held by it and (c) 3,083,847 Shares underlying the Warrants held by it, and (iii) Trading Fund OS beneficially owned 844,116 Shares, excluding (a) 96,934 Shares underlying the Pre-Funded Warrants held by it, (b) 549,601 Shares underlying the Common Warrants held by it and (c) 518,280 Shares underlying the Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 6,250,280 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 4,609,217 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 844,116 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 10,859,497 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 11,945,583 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 241,970 Shares held in the Partners Managed Account, which excludes (a) 35,438 Shares underlying the Pre-Funded Warrants held by it, (b) 200,876 Shares underlying the Common Warrants held by it and (c) 122,888 Shares underlying the Warrants held by it. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 11,945,583 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 11,945,583 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

Percent of class:

The following percentages are based upon a denominator that is the sum of: (i) 83,408,050 Shares outstanding as of August 12, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026, (ii) 36,047,919 Shares issued in the Issuer's direct offering, as reported in the Issuer's Prospectus Supplement filed with the Securities and Exchange Commission on October 1, 2026 and (iii) 119,443 Shares underlying certain Pre-Funded Warrants held by the Reporting Persons as applicable. As of the close

(b) of business on September 30, 2026, (i) BVF beneficially owned approximately 5.2% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.9% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.9% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.1% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account). (c) Number of shares as to which the person has: %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on July 10, 2026.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF I GP LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF II GP LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

Biotechnology Value Trading Fund OS LP

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF Partners OS Ltd.

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF GP HOLDINGS LLC

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF PARTNERS L P/IL

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

BVF INC/IL

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert, Authorized Signatory
Date: 11/16/2026

LAMPERT MARK N

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert
Date: 11/16/2026